News Release

2026/1/14

New Substance Patent Application for Highly Active RBM-006 (Anti-Autotaxin Aptamer) and its Drug Impact in a Mouse Model of Diabetic Retinopathy

TOKYO, January 14, 2026 - RIBOMIC, Inc. (TYO:4591), a clinical-stage pharmaceutical company specializing in aptamer therapeutics, has announced a new substance patent application for highly active RBM-006 (anti-autotaxin aptamer) and its promising therapeutic effects in a diabetic retinopathy model.

Autotaxin (ATX) is a crucial enzyme that produces lysophosphatidic acid (LPA), an important lipid mediator involved in maintaining biological functions. Its dysfunction is known to lead to abnormalities in many organs. Particularly in ophthalmic diseases, it has been suggested to be involved in the onset of conditions such as glaucoma, age-related macular degeneration, and vitreoretinopathy. Our company aims to develop novel therapeutic agents for these ophthalmic diseases using aptamers.

We have now successfully created a novel anti-ATX aptamer (RBM-006) that surpasses the activity of existing anti-ATX aptamers while also having a shorter chain length, and have completed the filing of a patent application for this new substance (JP Patent Application 2026-002511). Through our own research and collaborative studies with the Department of Ophthalmology at the University of Tokyo Faculty of Medicine using this novel aptamer, we are investigating its therapeutic effects on glaucoma, age-related macular degeneration, and diabetic retinopathy.

As part of this research, we discovered that RBM-006 significantly suppressed retinal hemorrhage in a mouse model of diabetic retinopathy induced by an anti-PDGFRβ antibody, which triggered pericyte detachment from the surrounding retinal vessels (see right figure). These results strengthen the intellectual property foundation for RBM-006 and suggest its potential as a therapeutic approach for diabetic retinopathy.



Currently, anti-VEGF drugs are the first-line treatment for diabetic retinopathy. However, since they prove ineffective in over half of patients even with long-term therapy, there is a

pressing need for novel therapeutic agents with different mechanisms of action. We believe the anti-ATX aptamer (RBM-006) has high potential to become a new drug meeting this need and position it as our core product following RBM-007 (umedaptanib pegol). Moving forward, we plan to explore early commercialization through partnerships with pharmaceutical companies.

As disclosed in our February 20, 2024 announcement, "Notice Regarding Issuance of the 17th Series of Stock Options (with Exercise Price Revision Clause) through Third-Party Allotment and Conclusion of Facility Agreement (with Exercise Suspension Designation Clause)," we have secured the necessary funding for the development of RBM-006 as an ophthalmic therapeutic and are advancing R&D according to the initial plan.

There are no changes to the full-year earnings forecast for the fiscal year ending March 2026.

Please visit the RIBOMIC website for more information.
https://www.ribomic.com/eng/

Forward-Looking Statements This announcement contains forward-looking statements relating to current plans, estimates, strategies, belief and the future performance of Company. These statements are based on Company's current expectations in light of the information and assumptions currently available so that Company does not promise the realization and these expectations may differ materially from those discussed in the forward-looking statements. These factors include, but not limited to, i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, ii) currency exchange rate fluctuations, iii) claims and concerns on the product safety and efficacy, iv) completion and News Release discontinuation of clinical trials, v) infringement of Company's intellectual property rights by third parties.
Information on pharmaceutical products (including products currently in development), which is included in this press release is not intended to constitute an advertisement or medical advice.

Contacts for inquiries or additional information:
RIBOMIC Inc.
ir.inquiry@ribomic.com